Cart
sales@molnova.com
Norcantharidin b
CAS No. 29745-04-8
Norcantharidin b( Endothall anhydride )
Catalog No. M20338 CAS No. 29745-04-8
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 45 | In Stock |
|
| 25MG | 64 | In Stock |
|
| 50MG | 96 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNorcantharidin b
-
NoteResearch use only, not for human use.
-
Brief DescriptionNorcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
-
DescriptionNorcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
-
In Vitro——
-
In Vivo——
-
SynonymsEndothall anhydride
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorEGFRc-Met
-
Research AreaCancer
-
IndicationCancer
Chemical Information
-
CAS Number29745-04-8
-
Formula Weight168.15
-
Molecular FormulaC8H8O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:33 mg/mL (196.25 mM)
-
SMILES[H][C@@]12[C@H]3CC[C@H](O3)[C@]1([H])C(=O)OC2=O
-
Chemical Name47-Epoxyisobenzofuran-13-dione hexahydro- (3a-alpha4-beta7-beta7a-alpha)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Qiu P Wang S Liu M et al. Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells[J]. BMC Cancer 2017 17(1):55.
molnova catalog
related products
-
SOMG-833
A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM.
-
Glesatinib
Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase.
-
PLB-1001
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM.
